HomeCompareYCRM vs JNJ

YCRM vs JNJ: Dividend Comparison 2026

YCRM yields 333333.33% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 YCRM wins by $8.099219044190773e+31M in total portfolio value
10 years
YCRM
YCRM
● Live price
333333.33%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.099219044190773e+31M
Annual income
$80,944,421,463,343,720,000,000,000,000,000,000,000.00
Full YCRM calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — YCRM vs JNJ

📍 YCRM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodYCRMJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, YCRM + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
YCRM pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

YCRM
Annual income on $10K today (after 15% tax)
$28,333,333.33/yr
After 10yr DRIP, annual income (after tax)
$68,802,758,243,842,160,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, YCRM beats the other by $68,802,758,243,842,160,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of YCRM + JNJ for your $10,000?

YCRM: 50%JNJ: 50%
100% JNJ50/50100% YCRM
Portfolio after 10yr
$4.0496095220953863e+31M
Annual income
$40,472,210,731,671,860,000,000,000,000,000,000,000.00/yr
Blended yield
99.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

YCRM
No analyst data
Altman Z
137.0
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

YCRM buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricYCRMJNJ
Forward yield333333.33%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$8.099219044190773e+31M$30.3K
Annual income after 10y$80,944,421,463,343,720,000,000,000,000,000,000,000.00$4,689.40
Total dividends collected$8.098906375781879e+31M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: YCRM vs JNJ ($10,000, DRIP)

YearYCRM PortfolioYCRM Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$33,344,033$33,333,333.33$10,592$272.30+$33.33MYCRM
2$103,911,171,366$103,875,493,250.26$11,289$357.73+$103911.16MYCRM
3$302,644,656,190,810$302,533,471,237,448.00$12,123$472.89+$302644656.18MYCRM
4$823,817,797,451,856,400$823,493,967,669,732,100.00$13,141$629.86+$823817797451.84MYCRM
5$2,095,836,995,961,804,000,000$2,094,955,510,918,530,000,000.00$14,408$846.81+$2095836995961804.00MYCRM
6$4,983,251,920,823,462,000,000,000$4,981,009,375,237,783,000,000,000.00$16,021$1,151.60+$4983251920823461888.00MYCRM
7$11,073,835,968,753,321,000,000,000,000$11,068,503,889,198,040,000,000,000,000.00$18,122$1,588.22+$1.1073835968753322e+22MYCRM
8$22,999,277,308,531,336,000,000,000,000,000$22,987,428,304,044,770,000,000,000,000,000.00$20,930$2,228.20+$2.2999277308531335e+25MYCRM
9$44,643,905,199,991,210,000,000,000,000,000,000$44,619,295,973,271,085,000,000,000,000,000,000.00$24,792$3,191.91+$4.464390519999121e+28MYCRM
10$80,992,190,441,907,720,000,000,000,000,000,000,000$80,944,421,463,343,720,000,000,000,000,000,000,000.00$30,274$4,689.40+$8.099219044190773e+31MYCRM

YCRM vs JNJ: Complete Analysis 2026

YCRMStock

Aureus Incrated, an exploration stage company, develops and explores for mineral properties in Nevada and Montana. It holds interest in the Keene Placer claims that cover an area of 19.67 acres located in Broadwater County, Montana; and Western Star Lode claim and Mill site, which covers an area of 13.22 acres located in the Confederate Gulch mining district in Broadwater County, Montana. The company was founded in 2013 and is based in Atlanta, Georgia. Aureus Incorporated is a subsidiary of Maverick, LLC.

Full YCRM Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this YCRM vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

YCRM vs SCHDYCRM vs JEPIYCRM vs OYCRM vs KOYCRM vs MAINYCRM vs ABBVYCRM vs MRKYCRM vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.